Page 229 – Channelchek

Release – Bowlero Corp. Opens Lucky Strike Miami

Posted on March 25, 2024March 25, 2024 by aweinsoff@channelchek.com

03/25/2024

RICHMOND, Va.–(BUSINESS WIRE)– Bowlero Corporation (NYSE: BOWL), the global leader in bowling entertainment, announced today the opening of Lucky Strike Miami, the second new build using the Lucky Strike brand since it was acquired in September. Lucky Strike Miami is located in the heart of Downtown Miami within Miami Worldcenter, a 27-acre, $6 billion mixed-use destination transforming Miami’s urban core with world-class shopping, dining, hospitality, and residential options, just steps away from the Kaseya Center, home to the Miami Heat.

“Lucky Strike Miami epitomizes our commitment to innovation and excellence,” stated Thomas Shannon, Founder, Chairman, and CEO of Bowlero Corp. “As we continue to strategically expand the Lucky Strike brand nationwide, this new location represents not only a new chapter in our growth but also a testament to our commitment to providing unparalleled experiences for guests across the country.”

Lucky Strike Miami is a 30,000 sq. ft. premier entertainment destination featuring 28 state-of-the-art bowling lanes and a contemporary aesthetic. Beyond bowling, this destination elevates leisure with its expansive arcade, a craft cocktail bar, and an intimate VIP room with six private bowling lanes. Lucky Strike Miami’s menu will consist of dynamic culinary concepts that feature luxe fair with quality ingredients while elevating traditional classics.

“Not only are we thrilled to be welcoming Lucky Strike to Miami Worldcenter, but we are excited to be bringing the beloved bowling brand back to Miami once again following its nearly decade-long run on Miami Beach,” said Nitin Motwani, Managing Partner of Miami Worldcenter Associates. “Lucky Strike will not only enhance Downtown Miami’s status as a family-friendly destination, but it will also be a wonderful complement to Miami Worldcenter’s various food, beverage, and entertainment options.”

Lev Ekster, President of Bowlero Corp., said in closing “Lucky Strike Miami embodies the vibrant ambiance of Miami, redefining the bowling experience for guests of all ages. Our mission extends beyond entertainment; it’s about creating memorable moments and fostering positive guest experiences. We look forward to this next chapter in Miami as we open our doors to the community.”

Lucky Strike Miami will open to the public on March 25th.

About Bowlero Corp.

Bowlero Corporation is one of the world’s premier operators of location-based entertainment. With approximately 350 locations across North America, the Company serves more than 40 million guest visits annually through a family of brands that include Lucky Strike, Bowlero, and AMF. In 2019, Bowlero acquired the Professional Bowlers Association, the major league of bowling and a growing media property that boasts millions of fans around the globe. For more information on Bowlero, please visit BowleroCorp.com.

About Miami Worldcenter:

Miami Worldcenter is a new $6 billion mixed-use destination in the heart of Downtown Miami. As one of the largest private urban real estate developments underway in the United States, the project occupies 27 acres spanning ten city blocks and offers world-class retail, hospitality, commercial and residential uses. Several phases of the project have already been completed and occupied, including three residential towers, a significant portion of the retail component, and a newly opened citizenM hotel.

Miami Worldcenter Associates serves as the master developer for the overall mixed-use development, led by Managing Partners Art Falcone and Nitin Motwani, in partnership with CIM Group, a community-focused real estate and infrastructure owner, operator, lender and developer. Together they have assembled a best-in-class development team that is currently transforming the urban core of Miami into one of the country’s largest mixed-use destinations. Learn more at www.miamiworldcenter.com.

For Media:

PR@BowleroCorp.com

mwc@schwartz-media.com

Source: Bowlero Corp

Release – Unicycive Therapeutics to Be Featured In Multiple Presentations At The Upcoming European Renal Association Congress

Posted on March 25, 2024March 25, 2024 by aweinsoff@channelchek.com

Research News and Market Data on UNCY

March 25, 2024 7:03am EDT Download as PDF

LOS ALTOS, Calif., March 25, 2024 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that multiple presentations will be delivered on the Company’s product candidates, oxylanthanum carbonate (OLC) and UNI-494, at the 61^st European Renal Association (ERA) Congress taking place May 23-26, 2024, in Stockholm, Sweden.

Shalabh Gupta, MD, Chief Executive Officer of Unicycive, commented, “The ERA Congress is one of the most prominent nephrology meetings of the year, and we are excited to deliver presentations on both OLC and UNI-494. In addition to presenting preclinical data supporting both of our programs, we will also be reporting on our two clinical trials in progress. We look forward to participating in this important event.”

Oxylanthanum Carbonate (OLC)

Title:	Enhanced Urinary Phosphorous Reduction: Comparative Study of Oxylanthanum Carbonate and Tenapanor in Rats
Lead Author:	Satya Medicherla, Ph.D., Vice President, Preclinical Pharmacology, Unicycive
Type:	Focused Oral Presentation
Dates/Times:	May 25, 2024 from 12:10 p.m. – 12:15 p.m. CEST

Title:	Oxylanthanum Carbonate for Hyperphosphatemia in End Stage Kidney Disease (ESKD): Tolerability Trial in Progress
Lead Author:	Pablo E. Pergola, M.D., Ph.D., Renal Associates, P.A.
Type:	ePoster
Date/Time:	Available throughout the conference

UNI-494

Title:	Oral Administration of UNI-494 Ameliorates Acute Kidney Injury in a Rat Model of Delayed Graft Function
Lead Author:	Satya Medicherla, Ph.D., Vice President, Preclinical Pharmacology, Unicycive
Type:	Focused Oral Presentation
Dates/Times:	May 25, 2024 from 12:00 p.m. – 12:05 p.m. CEST

Title:	UNI-494 Phase I Tolerability and Pharmacokinetics: Trial in Progress
Lead Author:	Guru Reddy, Ph.D., Vice President of Preclinical R&D, Unicycive
Type:	Focused Oral Presentation
Dates/Times:	May 25, 2024 from 12:45 p.m. – 12:50 p.m. CEST

About Oxylanthanum Carbonate (OLC)

Oxylanthanum carbonate is a next-generation lanthanum-based phosphate binding agent utilizing proprietary nanoparticle technology being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD). OLC has over forty issued and granted patents globally. Its potential best-in-class profile may have meaningful patient adherence benefits over currently available treatment options as it requires a lower pill burden for patients in terms of number and size of pills per dose that are swallowed instead of chewed. Based on a survey conducted in 2022, Nephrologists stated that the greatest unmet need in the treatment of hyperphosphatemia with phosphate binders is a lower pill burden and better patient compliance.¹ The global market opportunity for treating hyperphosphatemia is projected to be in excess of $2.5 billion in 2023, with the United States accounting for more than $1 billion of that total. Despite the availability of several FDA-cleared medications, 75 percent of U.S. dialysis patients fail to achieve the target phosphorus levels recommended by published medical guidelines.

Unicycive is seeking FDA approval of OLC via the 505(b)(2) regulatory pathway. As part of the clinical development program, two clinical studies were conducted in over 100 healthy volunteers. The first study was a dose-ranging Phase I study to determine safety and tolerability. The second study was a randomized, open-label, two-way crossover bioequivalence study to establish pharmacodynamic bioequivalence between OLC and Fosrenol. Based on the topline results of the bioequivalence study, pharmacodynamic (PD) bioequivalence of OLC to Fosrenol was established.

Fosrenol® is a registered trademark of Shire International Licensing BV.
¹Reason Research, LLC 2022 survey. Results here.

About Hyperphosphatemia

Hyperphosphatemia is a serious medical condition that occurs in nearly all patients with End Stage Renal Disease (ESRD). If left untreated, hyperphosphatemia leads to secondary hyperparathyroidism (SHPT), which then results in renal osteodystrophy (a condition similar to osteoporosis and associated with significant bone disease, fractures and bone pain); cardiovascular disease with associated hardening of arteries and atherosclerosis (due to deposition of excess calcium-phosphorus complexes in soft tissue). Importantly, hyperphosphatemia is independently associated with increased mortality for patients with chronic kidney disease on dialysis. Based on available clinical data to date, over 80% of patients show signs of cardiovascular calcification by the time they become dependent on dialysis.

Dialysis patients are already at an increased risk for cardiovascular disease (because of underlying diseases such as diabetes and hypertension), and hyperphosphatemia further exacerbates this. Treatment of hyperphosphatemia is aimed at lowering serum phosphate levels via two means: (1) restricting dietary phosphorus intake; and (2) using, on a daily basis, and with each meal, oral phosphate binding drugs that facilitate fecal elimination of dietary phosphate rather than its absorption from the gastrointestinal tract into the bloodstream.

About UNI-494

UNI-494 is a novel nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator. Mitochondrial dysfunction plays a critical role in the progression of acute kidney injury and chronic kidney disease. UNI-494 has a novel mechanism of action that restores mitochondrial function and may be beneficial for the treatment of several diseases including kidney disease. Unicycive is currently conducting a Phase 1 dose-ranging safety study in healthy volunteers in the United Kingdom that is expected to complete in 2H of 2024. UNI-494 is protected by issued patent(s) in the U.S. and Europe and a wide range of patent applications worldwide. UNI-494 has been granted orphan drug designation (ODD) by the U.S. Food and Drug Administration (FDA) for the prevention of Delayed Graft Function (DGF) in kidney transplant patients.

About Delayed Graft Function

Delayed Graft Function (DGF) refers to the acute kidney injury (AKI) that occurs in the first week after kidney transplantation, which necessitates dialysis intervention. As the name indicates, DGF can result in sub-optimal or impaired graft function and is one of the most common and serious complications of kidney transplantation. Poor kidney function in the first week of graft life is detrimental to the longevity of the allograft. DGF is also associated with higher rates of tissue rejection and decreased patient survival. Currently, there are no FDA approved drugs for the treatment of DGF.

Ischemia/reperfusion injury (IRI) is known to be a major causative factor for the AKI that results in DGF during kidney transplantation. Ischemic preconditioning, that works by activating K_ATPchannels in mitochondria, is a natural endogenous mechanism which protects cells from IRI in the heart, kidney, liver, and other organs. UNI-494 is a pharmacological approach that emulates and enhances this natural phenomenon of ischemic preconditioning.

About Unicycive Therapeutics

Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. UNI-494 is a patent-protected new chemical entity in late preclinical development for the treatment of acute kidney injury. For more information, please visit Unicycive.com and follow us on LinkedIn and YouTube.

Forward-looking statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as “anticipate,” “believe,” “forecast,” “estimated” and “intend” or other similar terms or expressions that concern Unicycive’s expectations, strategy, plans or intentions. These forward-looking statements are based on Unicycive’s current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidates; risks related to business interruptions, which could seriously harm our financial condition and increase our costs and expenses; dependence on key personnel; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled ‘Risk Factors’ in Unicycive’s Annual Report on Form 10-K for the year ended December 31, 2022, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Unicycive specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Investor Contact:

ir@unicycive.com
(650) 543-5470

SOURCE: Unicycive Therapeutics, Inc

Released March 25, 2024

One Stop Systems (OSS) – Reports Fourth Quarter and Fiscal Year Results

Posted on March 25, 2024March 25, 2024 by cpereira@noblefcm.com

Monday, March 25, 2024

One Stop Systems, Inc. (OSS) designs and manufactures innovative AI Transportable edge computing modules and systems, including ruggedized servers, compute accelerators, expansion systems, flash storage arrays, and Ion Accelerator™ SAN, NAS, and data recording software for AI workflows. These products are used for AI data set capture, training, and large-scale inference in the defense, oil and gas, mining, autonomous vehicles, and rugged entertainment applications. OSS utilizes the power of PCI Express, the latest GPU accelerators and NVMe storage to build award-winning systems, including many industry firsts, for industrial OEMs and government customers. The company enables AI on the Fly® by bringing AI datacenter performance to ‘the edge,’ especially on mobile platforms, and by addressing the entire AI workflow, from high-speed data acquisition to deep learning, training, and inference. OSS products are available directly or through global distributors. For more information, go to www.onestopsystems.com.

Joe Gomes, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

A Transformational Year. 2023 was a transformational year for OSS. The low margin digital business went away, a new management team and Board members were installed, and the Company is now firmly focused on large and rapidly growing global markets driven by AI and ML.

4Q23 Results. Revenue totaled $13.2 million, slightly above our $13 million estimate, but down 28% y-o-y, reflecting the continued runoff of the Disguise business, which contributed $3.1 million of revenue in the year ago quarter. Gross margin, however, rose 640 basis points to 33.7%. OSS net loss was $277,560, or a loss of $0.01/sh in the quarter, compared to a net loss of $3.3 million, or a loss of $0.16/sh last year. Adjusted EPS was $0.01/sh compared to a net loss of $0.14/sh last year. We had forecasted a loss of $0.07/sh.

Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

Haynes International (HAYN) – Special Shareholder Meeting is Scheduled for April 16

Posted on March 25, 2024March 25, 2024 by cpereira@noblefcm.com

Monday, March 25, 2024

Haynes International, Inc. is a leading developer, manufacturer and marketer of technologically advanced, nickel and cobalt-based high-performance alloys, primarily for use in the aerospace, industrial gas turbine and chemical processing industries.

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Special meeting of stockholders. Haynes International recently filed definitive proxy materials in anticipation of a special meeting of stockholders to vote on the company’s proposed merger with North American Stainless, Inc., a wholly owned subsidiary of Acerinox S.A. Acerinox is a leader in the manufacturing and distribution of stainless steel and high-performance alloys and will acquire all the outstanding shares of Haynes for $61.00 per share in an all-cash transaction. The special meeting of stockholders of Haynes International will be held virtually on Tuesday, April 16, 2024, at 9:30 am ET. Haynes stockholders of record as of the close on March 11 are entitled to vote the shares of Haynes International common stock held on the record date.

Closing is expected in the third calendar quarter. The waiting period under the Hart-Scott-Rodino Antitrust Improvements Act expired on March 18. Remaining closing conditions include approval of the merger under other applicable foreign investment laws and the adoption of the merger agreement by Haynes’ stockholders. The transaction is expected to close in the third calendar quarter of 2024.

Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.

Comtech Telecommunications (CMTL) – Some Encouraging News

Posted on March 25, 2024March 25, 2024 by cpereira@noblefcm.com

Monday, March 25, 2024

Comtech Telecommunications Corp. engages in the design, development, production, and marketing of products, systems, and services for advanced communications solutions in the United States and internationally. It operates in three segments: Telecommunications Transmission, Mobile Data Communications, and RF Microwave Amplifiers. The Telecommunications Transmission segment provides satellite earth station equipment and systems, over-the-horizon microwave systems, and forward error correction technology, which are used in various commercial and government applications, including backhaul of wireless and cellular traffic, broadcasting (including HDTV), IP-based communications traffic, long distance telephony, and secure defense applications. The Mobile Data Communications segment provides mobile satellite transceivers, and computers and satellite earth station network gateways and associated installation, training, and maintenance services; supplies and operates satellite packet data networks, including arranging and providing satellite capacity; and offers microsatellites and related components. The RF Microwave Amplifiers segment designs, develops, manufactures, and markets satellite earth station traveling wave tube amplifiers (TWTA) and broadband amplifiers. Its amplifiers are used in broadcast and broadband satellite communication; defense applications, such as telecommunications systems and electronic warfare systems; and commercial applications comprising oncology treatment systems, as well as to amplify signals carrying voice, video, or data for air-to-satellite-to-ground communications. The company serves satellite systems integrators, wireless and other communication service providers, broadcasters, defense contractors, military, governments, and oil companies. Comtech markets its products through independent representatives and value-added resellers. The company was founded in 1967 and is headquartered in Melville, New York.

Joe Gomes, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

New T&W President. Thursday after the market close, Comtech announced the hiring of Jeff Robertson as the Company’s new President of the Terrestrial and Wireless Networks business segment. Prior to joining Comtech, Mr. Robertson served as President and CEO of Intrado Life Safety, a firm specializing in first responder technology in North America.

Significant News. We view the hiring of Mr. Robertson positively on a couple of fronts. First, Intrado is a direct competitor to Comtech and we expect Mr. Robertson to be familiar with Comtech’s T&W capabilities. Mr. Robertson’s choice of joining Comtech speaks positively about Comtech’s T&W business, in our view. Secondly, his hire indicates that top level executives still view Comtech as an attractive option to work, even given the recent challenges.

Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

Government Shutdown Avoided With $1.2 Trillion Plan

Posted on March 25, 2024March 25, 2024 by slightbourne@noblecapitalmarkets.com

Congress succeeded in narrowly averting a partial government shutdown by passing a $1.2 trillion spending package, but the contentious process laid bare the dysfunctional politics plaguing Washington D.C. This brinkmanship threatens to erode economic confidence and financial market stability, posing risks that small cap investors must monitor closely.

The House of Representatives advanced the 1,012-page omnibus bill by the slimmest of margins on Friday, with the 286-134 vote squeaking by the two-thirds majority required under an expedited procedure. A faction of 112 Republican lawmakers opposed the bipartisan compromise negotiated by House Speaker Mike Johnson, characterizing it as a bloated spending measure drafted secretly. The rancorous divide even prompted Rep. Marjorie Taylor Greene to file a long-shot bid to remove Johnson from his leadership role.

The legislative turmoil then shifted to the Senate, where certain conservative members like Rand Paul and Tommy Tuberville signaled they could employ dilatory tactics to temporarily force a shutdown before the bill’s ultimate anticipated passage this weekend. While a short-term partial shutdown would have limited fallout for government operations with retroactive funding, the perpetual governance crises fomented by such maneuvers are deeply concerning for the economic outlook.

“This inability to govern pragmatically and reach reasonable compromise shakes confidence in American economic leadership at a pivotal juncture,” said Brendan Walsh, a partner at investment advisor Woodridge Partners. “The brinkmanship and uncertainty could undermine the environment for sustained earnings growth that small-cap companies rely upon.”

Lack of fiscal discipline, long-term economic foresight, and stable policymaking tends to breed volatility that markets abhor. With the looming prospect of a debt ceiling standoff on the horizon, the headwinds for equity investors are magnified. Buoyant stock valuations appear increasingly discordant with the actual deteriorating governance backdrop, suggesting potential downside risks are being underappreciated.

Indeed, major credit rating agencies have already taken action reflecting these dynamics. Fitch downgraded its U.S. sovereign debt rating in August 2022, citing escalating budgetary dysfunction as a primary factor. Similarly, Moody’s revised its U.S. outlook to negative last November amid the fiscal policy disarray, signaling another downgrade could materialize.

“The perpetual political dramas surrounding basic government funding operations speak to deeper systemic issues that have now directly threatened America’s pristine credit rating,” said Liz Young, head of investment strategy at Renaissance Capital. “This turmoil should be highly concerning for small-cap investors sensitized to economic shifts.”

While equity markets exhibited nonchalance toward this latest shutdown scare, previous prolonged political standoffs over the debt ceiling and government funding have periodically roiled stocks. The S&P 500 fell over 10% in summer 2011 as partisan factions brawled over raising the debt limit before an eleventh-hour resolution, exemplifying how swiftly sentiment can sour during such imbroglios.

With the upcoming debt ceiling fight potentially catalyzing another such conflict before year-end, watchful small-cap investors must be vigilant for escalating dysfunction that could provoke turbulent volatility.

“At a certain threshold, this unproductive political rancor manifests tangible economic and market consequences that can no longer be easily dismissed,” Walsh cautioned. “Preparing defensive postures and hedging strategies may be prudent to navigate potential volatility spawned by these self-inflicted crises.”

The latest spending package does provide several pro-growth provisions appealing to corporations, including increased funding for medical research, childcare, and other Democratic policy priorities. But ultimately, the bruising legislative process highlighted that divided government paralysis remains intractable in the nation’s capital.

As these drawn-out fiscal policy standoffs grow increasingly commonplace, the risks of ebbing economic confidence and corporate earnings growth may become more acute for small-cap equity investors. Monitoring this governance turmoil will be crucial for calibrating prudent portfolio positioning in the months ahead.

Release – Comtech Names Telecommunications and Public Safety Leader Jeff Robertson as President of Terrestrial & Wireless Networks Business Segment

Posted on March 22, 2024March 22, 2024 by aweinsoff@channelchek.com

Research News and Market Data on CMTL

March 21, 2024 04:05 PM Eastern Daylight Time

CHANDLER, Ariz.–(BUSINESS WIRE)–March 21, 2024– Comtech (NASDAQ: CMTL), a global technology leader, today announced the appointment of telecommunications and public safety industry leader Jeff Robertson as the Company’s new President of its Terrestrial and Wireless Networks business segment.

Prior to joining Comtech, Robertson served as President & CEO of Intrado Life Safety, a company specializing in first responder technology in North America. Under his leadership, Robertson enhanced Intrado Life Safety’s operating structure, implemented critical digital transformation initiatives, migrated legacy products to next-generation cloud-based infrastructures, improved employee retention, and strengthened key go-to-market partnerships in under four years. Intrado Life Safety was sold in 2023 for $2.4 billion under Robertson’s leadership.

Throughout his career, Robertson has held numerous leadership roles, including Senior Vice President of Public Safety for startup innovator RapidSOS, CEO of Airbus DS Communications North America, Vice President and General Manager of Intergraph’s public safety software division, CEO of TCI – TelControl, and CML Emergency Services. He was also the founding executive director of the 9-1-1 Industry Alliance.

“Jeff will be instrumental in helping Comtech continue to grow and capitalize on core business objectives,” said John Ratigan, Interim CEO of Comtech. “Jeff brings unique insights and deep industry expertise that are well aligned with our continued One Comtech journey, terrestrial and wireless technology developments, and long-term strategies in key markets.”

As President of the Terrestrial & Wireless Networks segment, Robertson will have P&L responsibility across the enterprise. Robertson will oversee all aspects of engineering, program management, operations, new product development, system design, strategic planning, and customer engagement for all Terrestrial & Wireless Networks areas of focus.

“I am thrilled to be a part of Comtech,” said Robertson. “Comtech already enjoys a leadership position in NG-911 solutions. I am excited to lead this business forward as we continue to help states and local governments around the world to provide the best possible public safety solutions for their communities. Comtech has the right people, products and culture to capture the opportunities ahead of us.”

Robertson has been involved in the field of public safety technology for over 25 years, serving as a sworn officer and deputy sheriff. He also has extensive experience in software development for the public safety sector and was awarded a U.S. Patent for Voice Over IP Delivery of 911 calls, which is widely used across the industry today.

Robertson graduated from the executive program at the Wharton School – University of Pennsylvania and received a degree in telecommunications from Toronto Metropolitan University.

About Comtech

Comtech Telecommunications Corp. is a leading global technology company providing terrestrial and wireless network solutions, next-generation 9-1-1 emergency services, satellite and space communications technologies, and cloud native capabilities to commercial and government customers around the world. Our unique culture of innovation and employee empowerment unleashes a relentless passion for customer success. With multiple facilities located in technology corridors throughout the United States and around the world, Comtech leverages our global presence, technology leadership, and decades of experience to create the world’s most innovative communications solutions.For more information, please visit www.comtech.com.

Forward-Looking Statements

Certain information in this press release contains statements that are forward-looking in nature and involve certain significant risks and uncertainties. Actual results and performance could differ materially from such forward-looking information. The Company’s Securities and Exchange Commission filings identify many such risks and uncertainties. Any forward-looking information in this press release is qualified in its entirety by the risks and uncertainties described in such Securities and Exchange Commission filings.

Contacts

Investor Relations
Maria Ceriello
631-962-7115
Maria.Ceriello@comtech.com

Media Contact
Jamie Clegg
480-532-2523
jamie.clegg@comtech.com

Reddit’s Soaring IPO: From Online Forums to $9.5 Billion Company

Posted on March 22, 2024March 22, 2024 by slightbourne@noblecapitalmarkets.com

The internet forum that helped launch the meme stock frenzy is now a multi-billion dollar public company itself. Reddit, the hugely popular online community made up of thousands of niche message boards, had a blockbuster stock market debut on Thursday.

Shares of Reddit, trading under the ticker RDDT on the New York Stock Exchange, skyrocketed 48% to close at $50.44, giving the company a lofty valuation of $9.5 billion. The explosive first day performance continues the hot streak for newly public tech companies in 2024 and underscores insatiable investor demand for businesses involved with artificial intelligence.

Reddit priced its initial public offering on Wednesday at $34 per share, raising around $750 million in the process with the company itself collecting $519 million. That IPO price was already at the top end of the expected range amid high demand, valuing Reddit at $6.5 billion on an exit from the private markets.

The robust valuation is a major achievement for Reddit, which was founded nearly 20 years ago in 2005 by the entrepreneur duo of Alexis Ohanian and current CEO Steve Huffman. For years, the site with its stark design and freewheeling discussion forums operated on a shoestring budget.

But Reddit’s popularity and influence exploded in recent years, fueled by the rise of viral meme culture and Internet subcultures. The company reported $804 million in revenue for 2023, up 20% from the prior year, as it started more aggressively monetizing the engaged audiences on its platform through advertising and other services.

While still unprofitable with a $90.8 million net loss last year, Reddit is now setting itself up as a major media and technology player by going public. It is the first major social platform to hit the public markets since Pinterest’s IPO in 2019.

“This is a huge milestone for Reddit and the team,” said CEO Steve Huffman, speaking to CNBC from the NYSE trading floor on the company’s debut day. “Our people and our community have built an internet culture that is now being embraced by the world.”

Reddit’s successful IPO provides an exit for some of the company’s longtime venture capital investors and big corporate backers like Tencent and Condé Nast’s parent company. But Huffman said Reddit also allocated a portion of shares in the IPO for its most devoted users and volunteer moderators who help run the site’s myriad discussion boards.

“The people make Reddit what it is,” said Huffman. “This is a chance for our most passionate folks to own a piece of that.”

Looking ahead, Reddit sees big growth potential in data licensing, particularly providing user content to artificial intelligence companies to train their language models and other software. The company revealed it has already inked data deals worth over $200 million in the next few years.

However, Reddit is facing a probe from the Federal Trade Commission over its practices of selling user data to AI firms. Regulators are examining whether proper disclosure was made to users about how their posts and comments would be monetized.

Privacy and safety issues are nothing new for Reddit, which has had to crackdown on toxic content and hate speech proliferating across its unruly message board communities. Huffman acknowledged those challenges, including the role Reddit played at the center of the meme stock mania that sent shares of GameStop and AMC soaring in bizarre market frenzies in 2021.

But as evidenced by its IPO haul, Reddit has still managed to attract both users and investors by providing an online home for all sorts of niche interests and subcultures to flourish – whether that’s stocks, cryptocurrencies, sports, hobbies, activism or adult content. And Reddit sees plenty of runway for growth by continuing to serve as the internet’s open marketplace of ideas.

“There are so many people around the world looking for their communities,” said Huffman. “We provide that, and we’re just getting started.”

Snail (SNAL) – Media Strategy Potentially Reaches New Audiences

Posted on March 22, 2024March 22, 2024 by cpereira@noblefcm.com

Friday, March 22, 2024

Snail is a leading, global independent developer and publisher of interactive digital entertainment for consumers around the world, with a premier portfolio of premium games designed for use on a variety of platforms, including consoles, PCs and mobile devices.

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Delivers animated series. The company’s highly anticipated series, ARK: The Animated Series, which stars Academy Award winning actors Michelle Yeoh and Russell Crowe, is now available on Paramount+. We believe the series can leverage Paramount’s 67.5 million subscribers to reach new audiences and potentially convert new viewers to ARK players. We view the release of ARK: The Animated Series as a significant step in the company’s crossover media strategy.

Animated series DLC. In unison with the release of ARK: The Animated Series, the company is releasing a new DLC package that includes four new character skins from the series. The DLC release aims to drive user engagement across platforms and offer content to existing players who are fans of the show and new players alike.

Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

Eledon Pharmaceuticals (ELDN) – First Transplant Of A Pig Kidney Uses Tegoprubart To Prevent Immune Rejection

Posted on March 22, 2024March 22, 2024 by cpereira@noblefcm.com

Friday, March 22, 2024

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

First Transplant Of A Genetically Modified Kidney To A Human. Eledon announced that tegoprubart, its drug in development to prevent organ transplant rejection, was used in the first transplant of an engineered pig kidney into a human patient. The kidney was genetically engineered by eGenesis, Inc, a company that has been collaborating with Eledon. Tegoprubart is currently in a Phase 2 clinical trial testing it against tacrolimus in prevention of kidney transplant rejection.

Eledon Has A Research Collaborated With eGenesis. The pig kidney was engineered by eGenesis, Inc, a company that formed a research collaboration with Eledon in January 2023. eGenesis has proprietary technology for engineering genetic changes to animal organs to make them compatible for transplantation into humans. As described in our Research Note on October 16, these genetic changes reduce the cross-species immunological barriers. The agreement allows eGenesis to use tegoprubart in its xenotransplantation research.

Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

1·800·Flowers.com, Inc. (FLWS) – Very Near Term View A Little Less Rosy

Posted on March 22, 2024March 22, 2024 by cpereira@noblefcm.com

Friday, March 22, 2024

For more than 45 years, 1-800-Flowers.com has offered truly original floral arrangements, plants and unique gifts to celebrate birthdays, anniversaries, everyday occasions, and seasonal holidays, and to deliver comfort during times of grief. Backed by a caring team obsessed with service, 1-800-Flowers.com provides customers thoughtful ways to express themselves and connect with the most important people in their lives. 1-800-Flowers.com is part of the 1-800-FLOWERS.COM, Inc. family of brands. Shares in 1-800-FLOWERS.COM, Inc. are traded on the NASDAQ Global Select Market, ticker symbol: FLWS.

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Highlights from New York NDR. This report features a recent Non-Deal Roadshow in New York with Bill Shea, Chief Financial Officer, and Andy Milevoy, Sr. Vice President, Investor Relations. In our view, the fireside chat discussion highlighted the dynamic revenue and cash flow growth opportunities, both organically and through acquisitions, and its solid financial position, all against the backdrop of favorable, long term secular trends toward e-commerce.

Very near term challenges. While most commodities have moderated, the company is still adversely affected by stubbornly high cocoa and sugar prices. Cocoa prices are not likely to moderate until 2025, a factor of drought conditions in Africa. In addition, while ocean freight prices are likely to be constrained as new ships come on line, domestic shipping costs are expected to increase.

Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

AZZ Inc. (AZZ) – Stock due for a pause after recent strength, rating lowered

Posted on March 22, 2024March 22, 2024 by cpereira@noblefcm.com

Friday, March 22, 2024

Michael Heim, Senior Vice President, Equity Research Analyst, Energy & Transportation, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

We are lowering our rating on the shares of AZZ to Market Perform with the stock solidly above our price target. The shares of AZZ have risen sharply in recent months and now trade above our $75 price target. At current prices, the shares trade at 16 times our recently raised fiscal 2025 earnings estimate, a multiple similar to its peers. Our investment premise for the shares of AZZ had been that its multiples would expand as the company’s balance sheet improved. This has largely come true.

A Market Perform rating does not mean we think the stock wont continue to rise. The company continues to report favorable results and lay the foundation for future growth. Construction of a new factory is nearing completion and financing costs are decreasing. A recent debt refinancing is expected to reduce financing costs by $5 million allowing us to raise our fiscal 2025 earnings estimate. With sales growing at a 3-5% rate and margins rising with a shift towards AZZ’s Metal Coating business, we expect solid earnings growth over the next few years.

Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

Release – MAIA Biotechnology Welcomes Prominent Medical Oncology Scientist Dr. Saadettin Kilickap to Its Scientific Advisory Board

Posted on March 21, 2024March 21, 2024 by aweinsoff@channelchek.com

Research News and Market Data on MAIA

March 21, 2024 3:00pm EDT

Acclaimed academic researcher has led 40+ multicenter phase 2 and phase 3 clinical studies

CHICAGO–(BUSINESS WIRE)– MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the appointment of Professor Saadettin Kilickap, M.D. to its Scientific Advisory Board (SAB).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240321173734/en/

Professor Saadettin Kilickap, M.D., Scientific Advisor to MAIA Biotechnology (Photo: Business Wire)

Dr. Kilickap is a professor at the Istinye University Faculty of Medicine, Department of Medical Oncology, Liv Hospital in Turkey. His research focuses on medical oncology and cancer epidemiology, including solid tumors such as lung cancer, breast cancer, melanoma, and gastrointestinal system cancers, as well as targeted therapies and immunotherapy.

“Saadettin has served as principal or sub-investigator in more than 40 national and international multi-center phase 2 and phase 3 studies, many of which were related to lung cancer,” said Chief Executive Officer Vlad Vitoc, M.D. “He is a prominent voice on medical oncology and cancer epidemiology, with a special interest in quality of life for cancer patients. We are delighted to welcome him as Scientific Advisor as we begin to clear major clinical inflection points this year and progress with our groundbreaking cancer research.”

Prior to his current appointment, Dr. Kilickap was a professor at the Preventive Oncology Department of Hacettepe University Cancer Institute of Turkey. Earlier he worked in the Department of Hematology-Oncology at Regensburg University in Germany and was a faculty member at the Sivas Cumhuriyet University Faculty of Medicine, Department of Internal Medicine, in Turkey.

Dr. Kilickap graduated with honors from Gazi University Faculty of Medicine and went on to complete his internal medicine residency training at Hacettepe University Faculty of Medicine, both located in Ankara, Turkey. He completed his fellowship training at Hacettepe and became a medical oncology specialist in 2009. In the same year, he graduated from the Cancer Epidemiology Master’s Program at the Hacettepe University Oncology Institute, Department of Preventive Oncology.

Dr. Kilickap has authored more than 240 scientific articles published in international peer-reviewed journals, and delivered more than 50 poster presentations at international congresses.

About MAIA Biotechnology, Inc.

MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.

Forward Looking Statements

MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, “MAIA,” “Company,” “we,” “our,” and “us” refers to MAIA Biotechnology, Inc. and its subsidiaries.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240321173734/en/

Investor Relations Contact
+1 (872) 270-3518
ir@maiabiotech.com

Source: MAIA Biotechnology, Inc.

Released March 21, 2024